FDA Clears Accelerated TMS Protocol for Major Depression

The FDA has cleared an accelerated protocol for a transcranial magnetic stimulation system in the treatment of depression and anxiety symptoms in major depressive disorder. Read More

FDA clears first digital treatment for depression, but experts caution that research is still early

The US Food and Drug Administration is allowing the use of Rejoyn, the first prescription digital treatment for major depressive disorder. Rejoyn, made by Otsuka Pharmaceutical and Click Therapeutics, ... Read More

FDA approves TMS device for adolescents with major depressive disorder

Apollo TMS Therapy delivers targeted stimulation to specific brain regions responsible for mood and emotional regulation.The FDA has granted 510(k) clearance to an Atlanta-based medical technology ... Read More

BrainsWay Shares Jump Following FDA Approval of Accelerated Depression Therapy

BrainsWay Ltd. (NASDAQ:BWAY) saw its stock rise 6.3% on Tuesday after the U.S. Food and Drug Administration (FDA) approved an accelerated treatment protocol for the company’s Deep Transcranial ... Read More

BWAY Shares Gain on FDA Nod for Accelerated Deep TMS Depression Care

BrainsWay Ltd. BWAY recently secured FDA clearance for an accelerated treatment protocol using its Deep Transcranial Magnetic Stimulation (TMS) system. The approval allows providers to treat patients ... Read More